Back
BMJ Open - Analysis of Controlled Human Infection Studies
web1daysooner.org·1daysooner.org/publications/
This resource is tangentially related to AI safety; it concerns research ethics and governance in biomedical challenge trials, which may offer analogies for risk-benefit governance frameworks but is not directly focused on AI safety topics.
Metadata
Importance: 18/100journal articlehomepage
Summary
1Day Sooner is an advocacy organization supporting volunteers for controlled human infection studies (challenge trials) in vaccine and treatment development. Their publications page compiles research and analyses, including BMJ Open studies, examining the ethics, safety, and policy dimensions of human challenge trials. This work is relevant to accelerating medical countermeasure development for pandemic preparedness.
Key Points
- •Focuses on controlled human infection studies (challenge trials) as tools for accelerating vaccine and therapeutic development
- •Advocates for ethical frameworks that allow informed volunteers to participate in deliberate infection trials
- •Publishes peer-reviewed analyses on risk, consent, and regulatory policy for challenge trials
- •Relevant to pandemic preparedness and the ethics of accelerating medical research timelines
- •Explores tradeoffs between individual risk acceptance and collective benefit in research ethics
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| 1Day Sooner | Organization | 60.0 |
Cached Content Preview
HTTP 200Fetched Mar 20, 202617 KB
[Skip to content](https://www.1daysooner.org/publications/#primary)
### The WHO pandemic agreement—securing Africa’s leadership in a fragmenting global order
**Nelson Aghogho Evaborhene, Jessica Oga, Yusuff Adebayo Adebisi, Echezona Ejike Udokanma, Newton Runyowa, Zacharia Kafuko, Shashika Bandara**, and **Chizaram Onyeaghala** (February 26, 2026), BMJ Global Health, [“The WHO pandemic agreement—securing Africa’s leadership in a fragmenting global order](https://gh.bmj.com/content/11/2/e020634)“
In May 2025, the World Health Assembly adopted the historic WHO Pandemic Agreement, aimed at strengthening global pandemic preparedness and equity. This legally binding treaty emerged from years of negotiation shaped by the COVID-19 pandemic’s stark inequities—particularly those experienced by African nations. While the treaty introduces important innovations, notably the Pathogen Access and Benefit-Sharing system, significant challenges remain. Ambiguities in equity commitments, geopolitical fragmentation and rising nationalism threaten effective implementation. For Africa, realising the treaty’s promise requires robust legal frameworks, enhanced manufacturing and regulatory capacities and sustainable financing mechanisms that reduce donor dependency. This analysis critically examines the treaty’s provisions and political economy, emphasising the need for enforceable obligations, continental leadership and multi-sectoral accountability. We propose the establishment of a Pandemic Peer Review Mechanism to embed political accountability at national and regional levels. Only through coordinated African leadership, institutional investment and global solidarity can the Pandemic Agreement deliver equitable health outcomes in a fracturing global order.
### Equitable partnerships to advance early-phase trials in sub-Saharan Africa
**Katherine E. Stott, Anthony E. Chirwa, Christine Cole, Kondwani Jambo, Neil French, David G. Lalloo, Marc Henrion, Richard FitzGerald, Zacharia Kafuko, Henry C. Mwandumba, Stephen B. Gordon**, and **Brian Ngwira**(February 11, 2026), Nature Health, [“Equitable partnerships to advance early-phase trials in sub-Saharan Africa”](https://www.nature.com/articles/s44360-025-00043-4#citeas)
Early-phase trials (phases 1 and 2) are pivotal in shaping decisions regarding the progression of investigational medicinal products to market, through the generation of key safety, pharmacometric, immunogenicity and early efficacy data. Historically, just 10% of investigational medicinal products obtain eventual approval for marketing, and approximately 40% fail to progress from phase 1 to phase 2. It is essential that data obtained in early-phase trials are relevant to key populations, to mitigate this attrition risk. Sub-Saharan Africa bears the greatest human disease burden per population globally. Despite this, fewer than 3% of clinical trials are conducted in Africa, and the vast majority that are undertaken are phase 3 trials; phase 1 trials
... (truncated, 17 KB total)Resource ID:
cf8e7c9bcad84eab | Stable ID: NzU3ZTVjZG